Skin & hair

When Insurance Calls Your Acne Visit Cosmetic

Save

A denial letter that says "cosmetic" rarely explains why in plain language, and the reason is almost always one of a handful of specific, identifiable triggers. This walks through what actually causes that denial, which acne treatments get mistakenly flagged most often, and the appeal path that tends to work.

Last updated: July 2026

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

What Actually Triggers a Cosmetic Denial

A cosmetic denial usually traces back to what the claim itself shows, not to any judgment about the patient's skin. Insurers process a diagnosis code paired with a procedure or drug code, and if the visit note didn't document severity, scarring, or psychosocial impact, the claim can look indistinguishable from an elective skincare visit even when the treatment plan was entirely standard. National guidelines treat acne as a medical diagnosis with a defined, evidence-based treatment ladder based on severity 1, but that clinical reality only reaches the payer if it's written into the chart and the claim.

The specific documentation that tends to matter is concrete: lesion counts or a severity grade, whether prior over-the-counter or topical treatments were tried and failed, and any note of scarring or distress. A chart that says only "acne, follow up" gives a claims processor nothing to distinguish the visit from a cosmetic consultation, regardless of what was actually discussed in the room.

The Treatments Most Often Flagged Wrongly

Certain acne treatments get flagged as cosmetic more often than others because of how they're coded or how they're commonly used outside dermatology. Oral isotretinoin, despite strong trial evidence for severe and scarring acne 2, is sometimes miscoded or requires prior authorization that wasn't obtained first. Spironolactone is FDA-approved for other conditions and used off-label for hormonal acne, and trial evidence supports it for that use in women 3, but an insurer's system may only recognize its on-label indications unless the diagnosis code on the claim is acne specifically.

Prior authorization gaps compound both problems: a drug that would otherwise be covered can still be denied if the authorization request wasn't filed before the prescription was filled, or if it listed a diagnosis code that doesn't match what the pharmacy claim shows. Confirming the diagnosis code on both the medical claim and the pharmacy claim match is a small check that prevents a large share of these denials.

Combination Topicals and Antibiotics Have Their Own Triggers

Combination topical therapy is another common trigger, because a benzoyl peroxide and retinoid combination can look, on paper, like a skincare routine rather than a prescription regimen. Evidence supports fixed-dose combination topicals as more effective and faster-acting than either ingredient alone 4, which is exactly the kind of clinical detail a denial letter never mentions but a documented rationale in the chart can support on appeal.

Oral antibiotics for acne run into a related but different issue: pharmacy benefit systems sometimes route them through general antibiotic formulary rules rather than dermatology-specific ones, which can trigger step-therapy requirements — proof that a topical was tried first — even when that step was already completed and simply wasn't documented clearly enough for the system to recognize it.

Reading the Denial Letter Before Doing Anything Else

Reading the denial letter itself is the first concrete step, because it states a specific reason code even when the plain-language summary just says "cosmetic." Common reasons include a missing or non-specific diagnosis code, a procedure billed under a cosmetic-exclusion clause, a missing prior authorization, or a mismatch between the drug prescribed and the diagnosis on file. That reason code determines which appeal argument actually applies — a documentation gap and a true coverage exclusion are fixed in completely different ways.

The explanation of benefits and the denial letter are not always the same document and are worth requesting together if only one arrived: the EOB shows what the plan paid and why in claims-processing shorthand, while the denial letter is meant to state the specific policy basis in plain language, and discrepancies between the two are themselves sometimes grounds for appeal.

Filing the Appeal

Appealing a mislabeled cosmetic denial usually starts with an internal appeal, which asks the same insurer to re-review the claim with additional documentation. A letter of medical necessity from the prescribing dermatologist — describing severity, scarring, prior treatments tried, and psychosocial impact — directly answers the gap most cosmetic denials come from, since it supplies exactly the clinical detail the original claim lacked. If the internal appeal fails, most plans are required to offer an external review by an independent third party not employed by the insurer.

Appeal deadlines are strict and plan-specific, typically ranging from 60 to 180 days from the denial date, and missing that window can close off the internal appeal entirely regardless of how strong the medical necessity argument is — checking the exact deadline printed on the denial letter before gathering documentation saves time that otherwise gets lost to a technicality.

When a Cosmetic Denial Is Actually Correct

Not every cosmetic denial is a mistake, and it helps to know the difference before appealing. Procedures aimed at scar appearance after acne has resolved — laser resurfacing, chemical peels, microneedling, subcision, or filler — sit in a genuinely gray zone, since evidence supports combination approaches for improving scar appearance 5 but many plans still classify scar-revision procedures as cosmetic regardless of the cause, distinct from treating active, inflamed acne itself.

Most insurers apply some version of a functional-impairment test to this gray zone: appearance-only improvement tends to be excluded, while a procedure addressing pain, restricted movement, or a documented skin breakdown has a stronger case for coverage. Asking a dermatologist directly whether a planned scar procedure is likely to be classified as cosmetic under that test, before scheduling it, avoids a surprise bill later.

If You're Uninsured or Paying Cash

For anyone uninsured or paying cash who gets billed well beyond what was expected, a separate federal protection applies regardless of the cosmetic-versus-medical question. Providers are required to give uninsured and self-pay patients a good faith estimate before scheduled care, and a bill that comes in at least $400 over that estimate can be disputed through a formal patient-provider resolution process 6 — a route worth knowing about even when the underlying dispute is really about how the visit was categorized.

That dispute process is filed directly with the federal government, not the provider, and does not require the patient to have first resolved the coding disagreement with the practice — the two tracks, a coding appeal with an insurer and a good-faith-estimate dispute for self-pay overages, can run in parallel rather than one blocking the other.

Common questions

Because claims processing runs on codes, not clinical judgment — if the diagnosis code, severity documentation, or drug indication on the claim doesn't clearly match a covered medical reason, the system can flag it as cosmetic by default. It's usually a documentation gap rather than a considered decision that the visit wasn't medical.

It can be, since spironolactone is FDA-approved for other conditions and its use for hormonal acne is off-label, even though trial evidence supports it for that purpose. A denial tied to this usually resolves once the diagnosis code and a prescriber's note both clearly document acne as the reason for the prescription.

Typically the diagnosis, its severity, prior treatments tried and their outcomes, any scarring or psychosocial impact, and why the current treatment is the appropriate next step under standard guidelines. A prescribing dermatologist writes this letter directly; it is the single document that most often reverses a cosmetic-coded denial.

Sometimes, but it is genuinely more likely to be classified as cosmetic than treatment of active acne itself, since the underlying disease process has typically resolved by the time scarring is addressed. Coverage, when it exists, usually depends on documented functional impact rather than appearance alone, and varies significantly by plan.

An internal appeal asks the same insurance company to re-review its own decision, usually with new documentation like a medical necessity letter. An external review, available if the internal appeal is denied, sends the claim to an independent third party unaffiliated with the insurer, and most plans are required to offer this option.

Related

Say it back

How would you explain this to someone you love?

Two or three sentences, just as you’d say it. Gale reflects back what you focused on — a mirror, not a quiz.

Talk to a clinician

Gale can help you find a clinician in your state and request a visit.

Find care →

When an Acne Flare Needs Prompt Care, Regardless of Billing

  • —sudden, severe cystic acne with fever, spreading redness, or facial swelling
  • —new or worsening mood changes, depression, or thoughts of self-harm while on an acne medication
  • —signs of a severe allergic reaction to a new prescription — facial swelling, difficulty breathing, or widespread hives

Thoughts of self-harm are a 988 or 911 emergency; facial swelling with difficulty breathing is a 911 emergency.

This article explains insurance billing and appeals for acne treatment and is not medical advice; it does not diagnose or evaluate any specific skin condition.

References

  1. 1.Reynolds RV, Yeung H, Cheng CE, et al. (2024). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology. PMID 38300170 ✓AAD guideline establishes acne as a medical diagnosis with a severity-based, evidence-graded treatment ladder, supporting that standard acne treatment is medically indicated rather than cosmetic.
  2. 2.Costa CS, Bagatin E, Martimbianco ALC, et al. (2018). Oral isotretinoin for acne. Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD009435.pub2Cochrane review evidence for isotretinoin's efficacy in severe acne, supporting that isotretinoin prescriptions for acne are evidence-based medical treatment rather than elective.
  3. 3.Santer M, Lawrence M, Renz S, et al. (2023). Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial. BMJ. PMID 37192767 ✓RCT evidence that spironolactone improves acne severity in women, supporting its off-label use for acne as a trial-backed clinical decision even though the drug's FDA approval covers other conditions.
  4. 4.McKeage K, Keating GM (2011). Adapalene 0.1%/benzoyl peroxide 2.5% gel: a review of its use in the treatment of acne vulgaris in patients aged ≥ 12 years. American Journal of Clinical Dermatology. PMID 21967116 ✓Evidence that fixed-dose adapalene/benzoyl peroxide combination gel is more effective than either component alone, supporting that combination topical prescriptions are a standard evidence-based regimen rather than a skincare routine.
  5. 5.Boen M, Jacob C (2024). Atrophic Postacne Scar Treatment: Narrative Review. JMIR Dermatology. link ✓Review of acne scar treatment modalities noting combination approaches outperform single modalities, used to describe the scar-revision procedures that plans often still classify as cosmetic.
  6. 6.Centers for Medicare & Medicaid Services (2024). No Surprises Act. CMS.gov (No Surprises Act portal). linkUninsured or self-pay patients billed at least $400 over their good faith estimate may dispute the bill through a federal patient-provider dispute resolution process.

6 sources, numbered by first appearance. General health information, not medical advice. AI-assisted editorial content — citations link their sources. Editorial policy

← Back to the health library